Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

45.47 -2.08 (-4.37%)
Streaming Delayed Price Updated: 3:03 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
35 36 Next >
News headline image
Why CRISPR Therapeutics Stock Crushed the Market Today ↗
Investors were cheered by the company's latest earnings release, coupled with operational updates. 
Via The Motley Fool
News headline image
Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus ↗
The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments. 
Via Investor's Business Daily
News headline image
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
News headline image
Why CRISPR Therapeutics Stock Is Moving Higher Monday ↗
CRISPR Therapeutics AG (NYSE: CRSP) shares are trading higher Monday after the company announced preclinical data for its investigational programs for the 
Via Benzinga
News headline image
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗
These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Charged Northward This Week ↗
Gene correction technology took a big step forward this week. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock: Bull vs. Bear ↗
Here's the scoop on one of the most widely followed gene-editing stocks on the market. 
Via The Motley Fool
News headline image
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
News headline image
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗
The meeting went almost as well as could be expected. 
Via The Motley Fool
News headline image
3 Healthcare Stocks to Buy Hand Over Fist in November ↗
Get these stocks while they're cheap. 
Via The Motley Fool
News headline image
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗
This stock could be a long-term winner, thanks to its game-changing technology. 
Via The Motley Fool
News headline image
Why Are Stocks Up Today? ↗
Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates. 
Via InvestorPlace
Topics Economy
News headline image
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? ↗
Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. 
Via InvestorPlace
News headline image
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗
The agency could soon approve a potential cure for sickle cell disease . 
Via Investor's Business Daily
News headline image
CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher? ↗
CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe. 
Via InvestorPlace
News headline image
AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
Major U.S. indices ended in the green on Tuesday, with the Dow gaining nearly 124 points or 0.4% to 33,052.87. 
Via Benzinga
Topics Stocks
News headline image
CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision ↗
Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now. 
Via InvestorPlace
News headline image
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
News headline image
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy ↗
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock. 
Via InvestorPlace
News headline image
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches ↗
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next  
Via Benzinga
News headline image
Vertex Pharmaceuticals: Buy at the High? ↗
Vertex shares have been flying high in recent times. 
Via The Motley Fool
News headline image
2 Fantastic Growth Stocks to Buy Hand Over Fist ↗
These stocks make great bargains today. 
Via The Motley Fool
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
Neither has performed well on the stock market this year. 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy Right Now for Less than $100 ↗
You can start with a small investment and win big over time. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Get In Now Before Investors Catch On ↗
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
News headline image
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗
Wood is going all in on gene editing. 
Via The Motley Fool
News headline image
3 Gene Editing Stocks to Generate Super-Charged Gains ↗
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
News headline image
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
News headline image
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗
 
Via Benzinga
News headline image
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges ↗
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.